Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112892 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00112892 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT00112892, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.
Interventions
- DRUG irinotecan hydrochloride
- DIETARY_SUPPLEMENT selenium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112892
The ClinicalTrials.gov registry entry for NCT00112892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00112892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112892 about?
NCT00112892 is a clinical study titled "Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor ...
What is the current status of trial NCT00112892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00112892?
The interventions under investigation include: irinotecan hydrochloride (DRUG), selenium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00112892?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.